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Commentary

Keeping an Open Mind: Challenges and Mysteries in Cancer
Cell Biology Research
—Yusuf Ebrahim
Cancer arises after a series of mutations or other alterations allows cells to bypass their normal
growth checkpoints and divide freely in the body. The body aims to prevent tumors from forming by
protecting the integrity of its cells’ DNA. One protein, p53, is so vital in this role that it is often
referred to as the “guardian of the genome.” In fact, more than
half of all human cancers are associated with malfunctions that
disrupt p53 function (1).
In a normal cell, p53 is activated during the growth cycle and, if
the cell has substantial mutations in its DNA, p53 journeys
from the cell’s cytoplasm to its nucleus to trigger apoptosis
(programmed cell death). Since normal p53 prevents tumors
by halting their spread, abnormalities in p53 might permit a
cell to become cancerous. In some of the cancerous cells I
studied with Dr. Walker, the seemingly unrelated protein
mortalin, which binds to p53, is overexpressed. This keeps p53
from entering the nucleus, and allows cancerous cells to
survive and divide (2). My research goal has been to
investigate this interaction, known as the “p53-mortalin
complex,” in patient-derived and other samples of human
cancer cells.

The author in the lab.

I received a Summer Undergraduate Research Fellowship (SURF) in
2016 to work in Professor Chuck Walker’s cell biology lab, where I had been involved since 2014. I
worked under the guidance of Dr. Walker and alongside other colleagues in the lab. My work during
that time focused on culturing cancer cells and investigating p53 within them. The various surprises I
experienced while working on my SURF project taught me that research won’t always be as clear-cut
as one might expect. I learned the importance of keeping an open mind and considering the
possibility of obstacles and unexpected outcomes in order to make sense of conflicting results.

Project and Challenges
Two chemical agents used in our lab, MKT-077 and withanone, have the potential to disrupt the p53mortalin complex by binding to mortalin. This means that they might be able to free p53 and allow it
to enter the nucleus to kill the cancer cells (2, 3). Because MKT-077 and withanone target the very
mechanism that allowed the cancer to form in the first place, they should have the ability to
discriminate between cancerous cells and healthy cells. This is in contrast to many chemotherapies in
use today, which target any actively dividing cells and often cause damage to healthy parts of the
body, promoting side effects such as hair loss or increased risk of infection. Withanone is an extract
of the plant ashwagandha, which has been used in traditional Indian herbal medicine for many years.
Although it has not been tested extensively with regard to the p53-mortalin complex, evidence
suggests that withanone should be effective in cases where the complex is present (3).
My project had two objectives. First, I sought to confirm the presence of the p53-mortalin complex in
the cells I was planning to use. Second, I tried to disrupt the complex using MKT-077 and withanone
and determine the effectiveness of these agents in allowing p53 to move to the nucleus and trigger
apoptosis. I planned to designate groups of cells as untreated, MKT-treated, or withanone-treated.
For each group, I chose a series of analytical techniques that could pinpoint p53 in the cell (to see
whether it was stuck in the cytoplasm or already in the nucleus) and determine the levels of cell
death by apoptosis.
Initially I planned to perform this experiment on samples of cancer cells derived directly from acute
myeloid leukemia (AML) patients. Results derived from patient samples can be more valuable than
those derived from established cell cultures available from the American Type Culture Collection
(ATCC), a library of cell lines. AML cells from patient samples are more like the cells that would be
treated in a real cancer patient, because they haven’t been growing in flasks for too long. They also
come from a variety of patients rather than only one, so they provide more widely applicable results
regarding the effects of the chemical agents. However, these patient samples are limited in number.
We realized our supply was low, so we would have little room for error in our experiments. Dr.
Walker and I decided at the start of the summer to first run the experiment with a neuroblastoma cell
line (called IMR-32), in order to make sure that our techniques and materials worked properly before
moving to the patient samples.
Cell lines, like IMR-32, are also derived from cancer patients, but they are grown in flasks for long
periods, which could cause them to become different over time. IMR-32 cells were derived from a
child who had neuroblastoma in 1967. While cells from culture may have changed from their original
source, they can be grown indefinitely, so if we needed to repeat part of the experiment, we could
simply prepare a new flask. In addition, because all IMR-32 cells were derived from the same patient
many years ago, they are roughly uniform and the results should show that the p53-mortalin complex
exists in either all of them or none of them, making our results easier to interpret. By changing the
sample cells, I learned that I had to be flexible and willing to deviate from the original design of the
experiment. The proposal I wrote for my project was theoretical and didn’t consider the specific

resources of the lab or the needs of the overall research project; when that information was brought
to light, we had to adapt and make some tweaks to the experiment.
At the beginning of the summer, I had trouble starting up a cell line from our lab’s vials of frozen cells.
I tried a few times to thaw these IMR cells, but initially they did not survive. Sometimes the cells
would give us false hope by surviving for a day or two before failing. Under the microscope, the cells
would start off looking healthy—round and firmly adhered to the bottom of the flask. But within a
few days, most of the cells would be floating and fragmented.
I was using vials that we’d frozen down ourselves in the past. We ordered a fresh vial of IMR cells
from the ATCC, a “library” that stores cells that are close to the original source of the line. This fresh
vial was successful, and I kept a culture of IMR cells going through the summer. We think that our
original vials weren’t working due to an incident that left the liquid nitrogen tank (where the cells
were stored) nearly empty the preceding fall, and due to a possible error made when the cells were
being frozen down. This experience led me through a sequence of troubleshooting: I initially
questioned the technique I was using to thaw the cells, then the culture medium we were feeding to
the cells, and finally the frozen vials themselves. After seeing that what I was doing wasn’t working, I
realized that I had to make a change each time rather than repeat the same procedure.

Starting the Treatments
When I had the cells growing successfully, I started treating them with withanone to observe its
effects, and I met my next obstacle. After the first treatment, I noticed under the microscope that the
cancer cells looked as happy as ever; subsequent tests showed no significant difference in the levels
of apoptosis, or cell death, between the withanone-treated cells and the untreated cells. Since the
treatment seemed ineffective, my first thought was to question the vial of withanone. After
inspecting it more closely, I discovered that it had expired. We ordered a new vial of withanone and
repeated the treatments, but even after increasing the treatment concentration and duration to the
maximum we had planned, the withanone-treated cells and the untreated cells appeared the same.
The withanone was just not working. This result confused me; prior knowledge told us that
withanone was supposed to disrupt the p53-mortalin complex in cells that have it (3). So if the
withanone was not working, and we were performing the experiment correctly, it might mean that,
contrary to our previous suspicions, the IMR cells don’t really have the p53-mortalin complex.
Regardless, I didn’t think more of the matter and carried on. Next, I used a technique called
immunocytochemistry to stain p53 in the IMR cells, and I used a microscope to observe the position
of p53. Even in the untreated cells, the centers of the cells lit up under the microscope after the stain,
which would indicate that most of the p53 was located in the nuclei of the IMR cells rather than in
their cytoplasm (Figure 1). At the same time, other members of the lab had run a number of
immunoblots, which can detect the presence of p53 in a solution of proteins, on separate solutions
containing the cytoplasm and nuclei of the IMR cells. These blots showed that there was a lot of p53
in the nuclei of the IMR cells and a relatively small amount of p53 in their cytoplasm. Since mortalin is

generally only found in the cytoplasm, this
would further imply that the IMR cells didn’t
have the p53-mortalin complex.

Figure 1. IMR-32 cells stained for p53, viewed under
fluorescent light. The glowing regions represent the
position of p53 in the cells. The centers of the cells are
lighting up more than their outer edges; if the stain was
performed correctly, this can be used to demonstrate
that p53 is located in the nucleus of IMR-32 cells.

The evidence suggesting that the IMR cells
might not have the p53-mortalin complex
was throwing me off, because, despite
seeming to be self-consistent, it contradicted
not only some literature we’d read, but also
my own past findings from the IMR cells (4).
However, I think that my past results were
not as comprehensive as those during my
summer work. Since I was facing some
conflicting evidence about whether or not the
p53-mortalin complex was in the IMR cells, I
needed to do some further testing to find out
what was true.

Next Steps
Because our research focuses on the p53-mortalin complex, the finding that this complex might not
be present in the IMR cells—if true—would mean that the IMR cells won’t be relevant to our next
research steps. However, I believe that even a negative result—the lack of something—is important,
because we could not have known it otherwise. Due to the earlier setbacks with starting the cells up
and repeating the withanone treatments,
we didn’t have a chance to test the MKT on
the IMR cells during the summer.
Nevertheless, we gained a lot more
experience with and knowledge about the
experiments and analyses we were
running.

Figure 2. IMR-32 cells stained for p53, viewed under normal
light. The brown spots represent the position of p53 in the
cells. The brown regions form a ring around the outer edges
of most of the cells; this would contradict previous findings
and show that p53 is located in the cytoplasm of IMR-32
cells.

Our next step will be to run similar tests on
the AML patient samples. I’m excited to
investigate the patient samples, because
they are so different to work with, but I am
also interested at looking further at what’s
going on in the IMR cells. In December
2016, I repeated the immunocytochemistry
for the IMR cells with a modified staining
procedure; this showed p53 in the
cytoplasm of the IMR cells (Figure 2). I used
a more definitive staining procedure again
in February 2017, which also showed p53 in

the cytoplasm of the IMR cells (Figure 3). My next step, therefore, will be to investigate whether it is
mortalin that is responsible for keeping p53 in the cytoplasm, by using a technique called coimmunoprecipitation, which can identify whether proteins are bound together. After that, depending
on the results, I might look more closely at the effects of MKT-077 and withanone on the IMR cells.

Figure 3. IMR-32 cells stained for p53, viewed under fluorescent light with two different filters. The
blue regions in the image on the left represent the cells’ nuclei, whereas the green regions in the
center image represent the position of p53 in the cells. The image on the right is the result of
merging the left and center images. This shows that p53 is located in the cytoplasm of IMR-32 cells,
because most of the green regions (p53) are concentrated outside the blue regions (nucleus).

Final Thoughts and Lessons
I learned a number of valuable lessons by performing this research, in addition to new lab methods. I
worked mostly independently on my project, with guidance from Dr. Walker, which allowed me to
make choices such as restructuring parts of the experiment based on the results I was seeing. Most of
all, I learned that it is important to actively keep an open mind, especially in science. It took me a
while to understand that withanone was not effective against the IMR cells, despite changing the
experiment repeatedly—new withanone, longer incubation times, higher concentrations—with the
assumption that I was running some part incorrectly because I wasn’t seeing the result I expected. It
was good that I repeated and changed the experiment to rule out other possibilities, but when I
accepted that the withanone just wasn’t working, I started thinking about why that might be and
changed my previous ideas about the IMR cells. In other words, I never expected to get unexpected
results. This lesson will be important in my goals moving forward—I hope to become a doctor, and
the ability to question myself and my previous ideas will be equally valuable in that setting. Because
of the support of my lab mates and my mentor, my undergraduate research in Dr. Walker’s lab has
been my favorite experience at the University of New Hampshire. I eagerly look forward to continuing
my work in the lab.
I would like to thank Dr. Walker for always instilling curiosity in me, guiding me in my research, and
providing me with invaluable support in my journey. I would also like to thank the Hamel Center for
Undergraduate Research for giving me the opportunity to conduct the research and making it all
possible. Finally, I would like to thank all the students, former students, and staff I’ve worked with in
the lab, who were always helping me in my project and providing me with company: Bria Frehner,
Jasmina Cesko, Brianna Looney, Seth McNutt, Andrew Morin, Harrison LeFlem, Professor Anne
Böttger, and Dylan Laprise.
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